verapamil has been researched along with Bone Cancer in 9 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "If verapamil was added after 4 days, the channel blocker did not diminish load-induced calcium incorporation." | 5.28 | Verapamil decreases cyclic load-induced calcium incorporation in ROS 17/2.8 osteosarcoma cell cultures. ( Banes, AJ; Vadiakas, GP, 1992) |
| "Etoposide was given daily (150 mg m-2 day-1) for three doses (each over 1 h); the first dose was given 12 h into the verapamil infusion." | 2.68 | Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. ( Cowie, FJ; Dick, G; Flanagan, RJ; Judson, I; McCarthy, PT; Phillips, M; Pinkerton, CR, 1995) |
| "Current drug treatment for human osteosarcoma may include multiple chemotherapeutic agents, such as doxorubicin, cisplatin, and methotrexate." | 1.31 | Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells. ( Ashihara, T; Gebhardt, MC; Hirasawa, Y; Kusuzaki, K; Mankin, HJ; Takeshita, H, 2000) |
| "If verapamil was added after 4 days, the channel blocker did not diminish load-induced calcium incorporation." | 1.28 | Verapamil decreases cyclic load-induced calcium incorporation in ROS 17/2.8 osteosarcoma cell cultures. ( Banes, AJ; Vadiakas, GP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Z | 1 |
| Wan, L | 1 |
| Han, Y | 1 |
| Meng, X | 1 |
| Yang, Q | 1 |
| Li, Y | 1 |
| Yu, Q | 1 |
| Shen, Z | 1 |
| Guo, C | 1 |
| Okada, T | 1 |
| Tanaka, K | 1 |
| Nakatani, F | 1 |
| Sakimura, R | 1 |
| Matsunobu, T | 1 |
| Li, X | 1 |
| Hanada, M | 1 |
| Nakamura, T | 1 |
| Oda, Y | 1 |
| Tsuneyoshi, M | 1 |
| Iwamoto, Y | 1 |
| Brach Del Prever, A | 2 |
| Massara, FM | 2 |
| Besenzon, L | 1 |
| Bianchi, M | 1 |
| Picci, P | 1 |
| Briccoli, A | 1 |
| Miniero, R | 2 |
| Cowie, FJ | 1 |
| Pinkerton, CR | 1 |
| Phillips, M | 1 |
| Dick, G | 1 |
| Judson, I | 1 |
| McCarthy, PT | 1 |
| Flanagan, RJ | 1 |
| Saroglia, EM | 1 |
| Soldano, S | 1 |
| Barisone, E | 1 |
| Leone, L | 1 |
| Arrighini, A | 1 |
| Andolina, M | 1 |
| Madon, E | 1 |
| Scotlandi, K | 1 |
| Serra, M | 1 |
| Manara, MC | 1 |
| Lollini, PL | 1 |
| Maurici, D | 1 |
| Del Bufalo, D | 1 |
| Baldini, N | 1 |
| Ramachandra, M | 1 |
| Ambudkar, SV | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
| Hrycyna, CA | 1 |
| Takeshita, H | 1 |
| Kusuzaki, K | 1 |
| Ashihara, T | 1 |
| Gebhardt, MC | 1 |
| Mankin, HJ | 1 |
| Hirasawa, Y | 1 |
| Vadiakas, GP | 1 |
| Banes, AJ | 1 |
1 trial available for verapamil and Bone Cancer
| Article | Year |
|---|---|
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resis | 1995 |
8 other studies available for verapamil and Bone Cancer
| Article | Year |
|---|---|
ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2013 |
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms | 2006 |
[Treatment of metastatic osteosarcoma with verapamil, cyclosporine and chemotherapy. A case report].
Topics: Bone Neoplasms; Chemotherapy, Adjuvant; Child; Combined Modality Therapy; Cyclosporine; Femur; Human | 1995 |
[Use of cyclosporin and verapamil in association with chemotherapy in the treatment of pediatric patients with advanced-stage neoplasms. A pilot study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cerebellar Neoplasms; Ch | 1994 |
Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 1994 |
Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Topics: 3T3 Cells; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; ATP Binding Cassette Transpor | 1996 |
Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Topics: Adenosine Triphosphate; Alkaline Phosphatase; Animals; Antibiotics, Antineoplastic; Antineoplastic A | 2000 |
Verapamil decreases cyclic load-induced calcium incorporation in ROS 17/2.8 osteosarcoma cell cultures.
Topics: Animals; Bone Neoplasms; Calcium; Depression, Chemical; Osteoblasts; Osteosarcoma; Rats; Stress, Mec | 1992 |